BACE1 and early-onset autosomal dominant Alzheimer disease: Dose dependent knnockdown ~50% and iRNA delivery was demonstrated by the strong mRNA (60%) and protein (62%) knockdown of BACE1, a therapeutic target in Alzheimer’s disease